Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

This study tests a combination of two drugs — acalabrutinib (a targeted therapy) and rituximab (an antibody therapy) — as a first-time treatment for older or frailer patients with Mantle Cell Lymphoma (MCL), a type of blood cancer, who may not be able to tolerate more intensive chemotherapy. **You may be eligible if...** - You are 60 years of age or older with a confirmed diagnosis of Mantle Cell Lymphoma - You have Stage II–IV disease that requires treatment - You are older (80+), have multiple other health conditions, or have heart problems that make standard intensive chemotherapy too risky - You have not previously been treated for MCL **You may NOT be eligible if...** - You are younger than 60 - You have already received treatment for MCL - You are otherwise fit enough for standard intensive chemotherapy (unless you opt for this milder approach) Talk to your doctor to see if this trial is right for you.